Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01111877
Other study ID # C-09-041
Secondary ID
Status Terminated
Phase N/A
First received April 26, 2010
Last updated January 31, 2012
Start date May 2010
Est. completion date November 2011

Study information

Verified date January 2012
Source Alcon Research
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Observational

Clinical Trial Summary

This study was conducted to describe the time to first incidence of otorrhea post tympanostomy tube insertion.


Recruitment information / eligibility

Status Terminated
Enrollment 1389
Est. completion date November 2011
Est. primary completion date November 2011
Accepts healthy volunteers No
Gender Both
Age group 6 Months to 12 Years
Eligibility Inclusion Criteria:

- Participants must be at least 6 months old and no more than 13 years of age at the time of enrollment scheduled for unilateral or bilateral myringotomy and tympanostomy tube insertion. Patients and/or child must read/sign informed consent and comply with requirement of the study.

Exclusion Criteria:

- There are no exclusion criteria.

Study Design

N/A


Related Conditions & MeSH terms


Locations

Country Name City State
United States Contact Alcon Call Center for Trial Locations Fort Worth Texas

Sponsors (1)

Lead Sponsor Collaborator
Alcon Research

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of, time to, and relationship of risk factors associated with otorrhea post tympanostomy tube insertion. Up to 1 year No
See also
  Status Clinical Trial Phase
Withdrawn NCT03347461 - Otiprio Versus Ciprodex Tympanostomy Tube Outcomes Phase 4
Recruiting NCT04807660 - Bacteriological Evaluation of Children With Otorrhea
Withdrawn NCT00956748 - N-Acetylcysteine as an Adjunct for Refractory Chronic Suppurative Otitis Media Phase 4
Terminated NCT02817347 - A Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea Phase 1/Phase 2